MD1003 (Biotin) encouraging for progressive MS

A phase III trial shows evidence that MD1003 (Biotin) may be a safe and effective way of treating progressive MS. After a year on treatment, 1 in 6 of the treatment group showed a decrease of at least 0.5 on the EDSS measure of disability compared to none in the placebo group. The application process to license the drug is expected to begin by the end of the year. Presented at the American Academy of Neurology (AAN) meeting. Neurology Advisor MedPage Today Progressive forms of MS - A to Z of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news